Which one is avatrombopag/Sukesin produced in China?

Avatrombopag/Su Kexin (Avatrombopag) The brand name of the original research version of Avatrombopag marketed in China is Su Kexin, while the domestic version is mainly produced by Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., and its product name is Avatrombopag Maleate Tablets (trade name: Qing'anxin). This domestic version was approved for marketing in December 2023, marking it as the first domestic generic drug in China and the first avatrombopag maleate tablets approved by the National Medical Products Administration.

Avatrombopag is the world's first oral thrombopoietin receptor agonist (TPO-RA) approved by the U.S. Food and Drug Administration (FDA) for the treatment of thrombocytopenia associated with chronic liver disease (CLD). Its launch has filled China's drug gap in this field. The original drug was developed by Dova Pharmaceuticals and received marketing approval in the United States in May 2018. It was subsequently launched in many countries and regions such as the European Union and Japan. In China, Fosun Pharma obtained AkaRx’s exclusive development and commercial rights for avatropopag in mainland China in March 2018, and successfully introduced avatropopag maleate tablets (trade name: Sucoxin) into the domestic market in April 2020.

The launch of the domestic version of avatrombopag maleate tablets (Qing'anxin) provides patients with more treatment options and also promotes intensified market competition. In addition to Nanjing Zhengda Tianqing Pharmaceutical, there may be many other companies that will launch domestic generic drugs. The launch of these generic drugs not only enriches the market supply, but also further reduces drug prices and improves patient accessibility and affordability.

Avatrombopag, as a second-generation oral TPO-RA, has rapid, durable and safe efficacy. It can rapidly increase platelet counts to safe levels in the short term, significantly reduce the risk of bleeding, and maintain platelet count stability over time. In addition, the drug is an oral preparation and is not restricted by food types, making it easy for patients to take and greatly improving patients' compliance and quality of life.